Immunopathogenesis of psoriasis and pharmacological perspectives

Journal of Rheumatology

Volumn 36, Issue SUPPL. 83, 2009, Pages 9-11

  Loffredo, Stefania ^a   Ayala, Fabio ^a   Marone, Giancarlo ^a   Delfino, Gabriele ^a   Stranges, Saverio ^a   Marone, Gianni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cells; Immunity; Psoriasis

Indexed keywords

ANGIOGENIC FACTOR; AUTOANTIGEN; CD161 ANTIGEN; CD94 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CHRONIC INFLAMMATION; CONFERENCE PAPER; DENDRITIC CELL; ENVIRONMENTAL FACTOR; GRANULOCYTE; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; MAST CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE SUBPOPULATION; ARTICLE; CELLULAR IMMUNITY; EPIDERMIS; IMMUNOLOGY; PATHOPHYSIOLOGY; PSORIATIC ARTHRITIS;

ARTHRITIS, PSORIATIC; EPIDERMIS; HUMANS; IMMUNITY, CELLULAR;

EID: 70349915960     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090210     Document Type: Conference Paper

References (28)

1. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54:S67-80.
2. Loffredo S, Ayala F, Marone GG, Genovese A, Marone G. Immunopathogenesis of psoriasis and psoriatic arthritis and pharmacological perspectives. Reumatismo 2007;59:28-39.
3. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-957 (Pubitemid 47300009)
4. Cosmi L, De Palma R, Santarlasci V, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008;205:1903-1916
5. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-2587 (Pubitemid 44833335)
6. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-592 (Pubitemid 46220818)
7. Wraith DC, Nicolson KS, Whitley NT. Regulatory CD4+ T cells and the control of autoimmune disease. Curr Opin Immunol 2004;16:695-701. (Pubitemid 39423656)
8. Waldmann H. Immunology: protection and privilege. Nature 2006;442:987-988
9. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T cell tolerance. Nature 2006;442:997-1002.
10. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164-173 (Pubitemid 40007402)
11. Kay AB. Natural killer T cells and asthma. N Engl J Med 2006;354:1186-1188
12. Rogalski C, Meyer Hoffert U, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 2002;118:49-54. (Pubitemid 34107423)
13. Marone G, Triggiani M, de Paulis A. Mast cells and basophils: friends as well as foes in bronchial asthma? Trends Immunol 2005;26:25-31.
14. Fischer M, Harvima IT, Carvalho RF, et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation independent chemokine secretion. J Clin Invest 2006;116:2748-2756 (Pubitemid 44511638)
15. Theoharides TC,Donelan JM, PapadopoulouN, Cao J,KempurajD, Conti P. Mast cells as targets of corticotropin releasing factor and related peptides. Trends Pharmacol Sci 2004;25:563-568 (Pubitemid 39371146)
16. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005;174:7665-7675 (Pubitemid 40806271)
17. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 2006;54:S85-91.
18. de Paulis A, Prevete N, Fiorentino I, et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006;177:7322. (Pubitemid 44715102)
19. Detoraki A, Staiano RI, Granata F, et al. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic, lymphangiogenic, and proinflammatory effects. J Allergy Clin Immunol 2009;123:1142.
20. Detmar MM, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-1146 (Pubitemid 24256627)
21. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular specific growth factors and blood vessel formation. Nature 2000;407:242-248
22. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001;116:713-720 (Pubitemid 32467649)
23. Patella V, Giuliano A, Bouvet JP, Marone G. Endogenous superallergen protein Fv induces IL 4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. J Immunol 1998;161:5647-5655 (Pubitemid 28519132)
24. Marone G, Triggiani M, Genovese A, de Paulis A. Role of human mast cells and basophils in bronchial asthma. Adv Immunol 2005;88:97-160. (Pubitemid 41437913)
25. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991;88:4220-4224 (Pubitemid 21914511)
26. Ackermann L, Harvima IT, Pelkonen J, et al. Mast cells in psoriatic skin are strongly positive for interferon gamma. Br J Dermatol 1999;140:624-633 (Pubitemid 29191379)
27. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon gamma, interleukin 2, and tumor necrosis factor alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-759
28. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-130 (Pubitemid 38076484)